Clinical Trial ResultsInterim NEXICART-2 trial data appeared encouraging, with a 100% response rate and a 70% hematologic complete response rate without observed relapses or progression.
Market OpportunityThere are currently no FDA-approved agents available for treatment of relapsed/refractory AL amyloidosis, highlighting the potential market opportunity for NXC-201.
Regulatory DesignationThe FDA granted RMAT designation to NXC-201, which is being evaluated in NEXICART-2 trial for the treatment of relapsed/refractory AL Amyloidosis.